Epigenetic and Cellular Reprogramming of Doxorubicin-Resistant MCF-7 Cells Treated with Curcumin.

Area of Science:

• Molecular Biology
• Epigenetics
• Cancer Research

Background:

• Acquired multidrug resistance (MDR) in breast cancer, exemplified by the MCF-7R cell line, is a significant therapeutic challenge.
• Multidrug resistance is often mediated by P-glycoprotein (P-gp) overexpression and epigenetic alterations.
• Existing P-gp inhibitors have limitations for in vivo use due to nonspecific effects.

Purpose of the Study:

• To investigate the molecular mechanisms by which curcumin, a natural compound, affects multidrug-resistant (MDR) breast cancer cells (MCF-7R).
• To analyze curcumin's impact on gene expression related to DNA methylation and transcription, including the MDR1 gene.
• To identify epigenetic modifications induced by curcumin using reduced representation bisulfite sequencing.

Main Methods:

• Utilized the MCF-7R breast cancer cell line, a model for acquired multidrug resistance.
• Analyzed gene expression profiles related to epigenetic regulation and transcription.
• Employed reduced representation bisulfite sequencing to assess DNA methylation changes.
• Evaluated the reversal of the resistant phenotype in response to curcumin treatment.

Main Results:

• Curcumin treatment modulated gene expression involved in DNA methylation and transcription, including ABCB1/MDR1.
• Epigenetic modifications were identified in MCF-7R cells following curcumin exposure.
• Curcumin influenced cellular processes such as ribosome biogenesis and cytoskeletal dynamics.
• The resistant phenotype of MCF-7R cells was reversed towards that of sensitive cells.

Conclusions:

• Curcumin demonstrates potential as an adjuvant therapy to overcome chemoresistance in breast cancer.
• Curcumin's ability to modulate epigenetic regulation offers a novel approach to re-sensitize resistant cancer cells.
• Targeting epigenetic mechanisms with compounds like curcumin presents new pharmacological strategies for cancer treatment.